Physician profile
Gary P Manuel
NPI 1376525469
$2,379.69
in general payments reported to CMS, 2019-2025
27 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $40.66 · 2021: $536 · 2022: $200 · 2023: $527 · 2024: $347 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.51 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $346.39 | 2021-2025 | |
| Astellas Pharma US INC | $230.06 | 2023-2025 | Veozah |
| Amgen INC. | $187.43 | 2019-2023 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $159.27 | 2019-2024 | |
| Pfizer INC. | $159.03 | 2019-2025 | |
| Hologic Sales and Service, LLC | $130.22 | 2023-2025 | Aptima, Myosure Tissue Removal Device, Novasure |
| Ethicon US, LLC | $113.20 | 2022-2025 | Vistaseal, Evarrest |
| Organon LLC | $97.47 | 2024-2025 | Nexplanon, Jada System |
| Novo Nordisk INC | $83.50 | 2023-2025 | Wegovy |
| Therapeuticsmd, INC. | $66.52 | 2019-2022 | |
| Radius Health, INC. | $55.42 | 2024-2025 | Tymlos |
| Millicent US INC | $52.41 | 2025 | Femlyv, Intrarosa |
| Sage Therapeutics, LLC | $37.71 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $32.24 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $27.44 | 2019 | |
| Amag Pharmaceuticals, INC. | $24.80 | 2019 | |
| Axsome Therapeutics, INC. | $21.51 | 2025 | Auvelity |
| Coloplast Corp | $21.06 | 2023 | Saffron |
| Teleflex LLC | $20.74 | 2019 | |
| Agile Therapeutics, INC. | $20.71 | 2022 | |
| Exact Sciences Corporation | $19.09 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $16.43 | 2024 | Zepbound |
| Aspira Women'S Health INC | $16.08 | 2024 | Ova1 |
| Smith+Nephew, INC. | $14.30 | 2025 | Pico |
| Duchesnay USA Incorporated | $12.71 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Manuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.